| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Fibroblast growth factor 21;FGF-21;FGF21;UNQ3115/PRO10196; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human FGF21 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-FGF21 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AG-6; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC (as provided in the source record). Boster Bio Anti-FGF21 Rabbit Monoclonal Antibody catalog # M00802. Tested in WB, IHC applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: FGF21 (Fibroblast growth factor 21).
- Antibody format: Monoclonal; clone AG-6; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
FGF21 (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression). Activity requires the presence of KLB. . Reported cellular localization context: Secreted . Tissue expression notes (as provided): Ubiquitous.
Research relevance and current trends
- Research context keywords from the source record include: Angiogenesis,Cancer,Cardiovascular,Growth Factors,Growth Factors/Hormones,Signal Transduction.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
Workflow ideas (metafield): Validate FGF21 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect FGF21 expression by Western blot in cell or tissue lysates, Detect FGF21 in FFPE tissue sections by immunohistochemistry
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 63 kDa; calculated MW: 22300 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 63 kDa
- Cellular localization (provided): Secreted .
- Tissue details (provided): Ubiquitous.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
